Dublin, April 17, 2017 -- Research and Markets has announced the addition of the "Global Nootropics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 to 2024" report to their offering.
The global nootropics market was valued at USD 1,346.5 Mn in 2015, and is expected to reach USD 6,059.4 Mn by 2024, expanding at a CAGR of 17.9% from 2016 to 2024.
Nootropics, also known as cognitive enhancers are drugs and natural extracts that improve cognitive functions such as memory, creativity, motivation in healthy individuals. Nootropics have been available in the market for several decades and were made of ingredients such as multivitamins and caffeine - substances that the FDA has approved as dietary supplements and classified as GRAS (generally regarded as safe). At present, these products are being repackaged, repurposed and sold to academic and professional overachievers to augment their brain function. Companies operating in this space primarily succeed as lifestyle brands through smart marketing. However they can only be recognized as healthcare brands only after they develop products that secure regulatory approval thus establishing certified efficacy and safety to their products.
Among the key applications of nootropics, memory enhancement currently holds the largest revenue share and it is anticipated that the segment will maintain its lead through the forecast period 2016-2024. Major factors favoring the demand for memory enhancing nootropics include growing awareness among students and executives about the promised benefits of nootropics, easy accessibility, and the booming market for supplements. The memory enhancing nootropic drugs enhance learning and memory effect, enhance the ability of learned behaviors to resist disruption, enhance the efficiency of your brain functions and protect the brain from chemical injuries. Memory enhancement segment for nootropics was valued at USD 391.6 Mn in 2015.
Geographically, North America is the largest consumer of nootropics and is also characterized by domicile of topmost market players. Large population pool, high awareness in consumer population for preventive and cognitive health, rise of the self-directed consumer, and channel proliferation are the key factors driving the dominance of North America nootropics market. On the other hand, Asia Pacific is anticipated to be the fastest progressing regional market for nootropics. While in countries like China and India having a great history of natural and herbal based cognitive drugs that boosts the brain functions and other body functions, the foreign investment in collaboration with the local players have determined substantial growth in the nootropics market and the overall dietary supplements market.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
2.1 Global Nootropics Market Portraiture
2.2 Global Nootropics Market, by Type of Application, 2015 (USD Mn)
2.3 Global Nootropics Market Share, by Geography, 2015 (Value %)
Chapter 3 Nootropics Market Analysis
3.1 Global Nootropics Market Overview
3.2 Top 30 Drug Profiles
3.2.1 Adrafinil
3.2.2 Phenylpiracetam (Phenotropil)
3.2.3 Noopept
3.2.4 Sulbutiamine
3.2.5 Pramiracetam
3.2.6 Sunifiram
3.2.7 Piracetam
3.2.8 Oxiracetam
3.2.9 Aniracetam
3.2.10 Magnesium Citrate
3.2.11 Alpha- GPC
3.2.12 CDP-choline
3.2.13 Gynostemma
3.2.14 Ashwagandha
3.2.15 Bacopa Monnieri
3.2.16 Phenibut
3.2.17 Rhodila Rosea
3.2.18 Galantamine
3.2.19 Phenylethylamine (PEA)
3.2.20 Alpha-Lipoic Acid (ALA)
3.2.21 Uridine Monophosphate
3.2.22 Centrophenoxine
3.2.23 L-Dopa
3.2.24 N-Acetyl-Cysteine
3.2.25 L-theanine
3.2.26 Acetyl L-Cartinine
3.2.27 Huperzine A
3.2.28 Picamilon
3.2.29 Vinpocetine
3.2.30 Ginkgo Biloba
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Booming Supplements Industry
3.3.1.2 Sales Channel Proliferation
3.3.2 Challenges
3.3.2.1 Increase in Regulatory Pressures
3.3.3 Opportunities
3.3.3.1 Growth of E-commerce
3.4 Attractive Investment Proposition
3.5 Competitive Landscape of Key Players in Nootropics Market
Chapter 4 Global Nootropics Market Analysis, by Applications
4.1 Introduction
4.2 Memory Enhancement
4.3 Mood and Depression
4.4 Attention and Focus
4.5 Longevity and Anti-aging
4.6 Sleep, Recovery and Dream Enhancement
4.7 Anxiety
Chapter 5 Global Nootropics Market, By Geography
Chapter 6 Company Profiles
6.1 Nootrobox, Inc.
6.2 Cephalon, Inc.
6.3 Purelife Bioscience Co. Ltd.
6.4 Peak Nootropics
6.5 Nootrico
6.6 SupNootropic Biological Technology Co. Ltd.
6.7 AlternaScript LLC
6.8 Accelerated Intelligence, Inc.
6.9 Onnit Labs LLC
6.10 Powder City LLC
6.11 Ceretropic
6.12 Nootropic Source
6.13 Clarity Nootropics
For more information about this report visit http://www.researchandmarkets.com/research/65hht2/global_nootropics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vitamins and Dietary Supplements


Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 



